tiprankstipranks
Advertisement
Advertisement

DNPUF Stock Latest News

Sumitomo Pharma Refinances Guaranteed Debt With New Bridge Loan
Company AnnouncementsSumitomo Pharma Refinances Guaranteed Debt With New Bridge Loan
3d ago
Sumitomo Pharma Launches Major Share Offering to Strengthen Financial Base
PremiumCompany Announcements
Sumitomo Pharma Launches Major Share Offering to Strengthen Financial Base
3d ago
Sumitomo Pharma to Book ¥48.3 Billion Dividend as Non-Operating Income With No Group Profit Impact
PremiumCompany Announcements
Sumitomo Pharma to Book ¥48.3 Billion Dividend as Non-Operating Income With No Group Profit Impact
17d ago
Sumitomo Pharma Wins Conditional Japan Approval for First iPS Cell-Derived Parkinson’s Therapy
PremiumCompany Announcements
Sumitomo Pharma Wins Conditional Japan Approval for First iPS Cell-Derived Parkinson’s Therapy
1M ago
Sumitomo Pharma Launches ‘Boost 2028’ Plan to Build on V-Shaped Recovery
PremiumCompany Announcements
Sumitomo Pharma Launches ‘Boost 2028’ Plan to Build on V-Shaped Recovery
1M ago
Sumitomo Pharma Lifts Full-Year Profit Outlook on Strong GEMTESA Sales and Weaker Yen
PremiumCompany AnnouncementsSumitomo Pharma Lifts Full-Year Profit Outlook on Strong GEMTESA Sales and Weaker Yen
1M ago
Sumitomo Pharma Files ¥140 Billion Shelf Registration to Fund Growth and Bolster Finances
Premium
Company Announcements
Sumitomo Pharma Files ¥140 Billion Shelf Registration to Fund Growth and Bolster Finances
1M ago
Sumitomo Pharma’s iPS Cell Parkinson’s Therapy Heads to Key Japan Regulatory Review
Premium
Company Announcements
Sumitomo Pharma’s iPS Cell Parkinson’s Therapy Heads to Key Japan Regulatory Review
2M ago
Sumitomo Pharma Posts Surging Profit and Higher Revenue in Q3 FY2025 Under IFRS
PremiumCompany Announcements
Sumitomo Pharma Posts Surging Profit and Higher Revenue in Q3 FY2025 Under IFRS
2M ago
Sumitomo Pharma Outlines Q3 FY2025 Results With Caution on Forward-Looking Data
PremiumCompany Announcements
Sumitomo Pharma Outlines Q3 FY2025 Results With Caution on Forward-Looking Data
2M ago
Is DNPUF a Buy, Before Earnings?
PremiumPre-Earnings
Is DNPUF a Buy, Before Earnings?
2M ago
Sumitomo Pharma Reports Strong Half-Year Results and Raises Full-Year Forecasts
PremiumCompany Announcements
Sumitomo Pharma Reports Strong Half-Year Results and Raises Full-Year Forecasts
5M ago
Sumitomo Pharma Completes Strategic Sale in Asian Business Restructuring
PremiumCompany AnnouncementsSumitomo Pharma Completes Strategic Sale in Asian Business Restructuring
5M ago
DNPUF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
DNPUF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
Sumitomo Pharma upgraded to Equal Weight from Underweight at Morgan Stanley
Premium
The Fly
Sumitomo Pharma upgraded to Equal Weight from Underweight at Morgan Stanley
8M ago
Sumitomo Pharma Reports Significant Foreign Exchange Loss in Q1
PremiumCompany Announcements
Sumitomo Pharma Reports Significant Foreign Exchange Loss in Q1
8M ago
Sumitomo Pharma Completes Asian Business Transfer to Marubeni
PremiumCompany Announcements
Sumitomo Pharma Completes Asian Business Transfer to Marubeni
8M ago
Sumitomo Pharma Strengthens U.S. Market Position with Asset Assignment
PremiumCompany Announcements
Sumitomo Pharma Strengthens U.S. Market Position with Asset Assignment
10M ago
Sumitomo Pharma Highlights Independence Amid Parent Company Ties
PremiumCompany Announcements
Sumitomo Pharma Highlights Independence Amid Parent Company Ties
10M ago
Sumitomo Pharma Restructures Asian Business with Marubeni Partnership
PremiumCompany AnnouncementsSumitomo Pharma Restructures Asian Business with Marubeni Partnership
11M ago
Sumitomo Pharma Unveils ‘Reboot 2027’ for Strategic Growth
Premium
Company Announcements
Sumitomo Pharma Unveils ‘Reboot 2027’ for Strategic Growth
11M ago
Sumitomo Pharma Announces Significant Share Transfer in Asian Business
Premium
Company Announcements
Sumitomo Pharma Announces Significant Share Transfer in Asian Business
11M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >